 Hello, this is David McDermott from Beth Israel Deaconess Medical Center, a medical oncologist who focuses on treating kidney cancer. One of my roles is I have taken over for Dr. Mike Atkins as the leader of the Spore Grant in kidney cancer that's headquartered here in Boston. The Spore Grant is a grant from the National Cancer Institute that provides my colleagues and I with a large amount of funding over a five-year period to focus on improving outcomes for patients with kidney cancer, and it's given to us to try to speed the time it takes us to bring discoveries from the laboratory to patients by fostering what's called translational research where we study information that we obtain often from people with kidney cancer from sampling their tumors and blood and bring that information back to the laboratory in hopes of finding better treatments for this disease as well as better ways to detect it earlier on in this condition so we can improve outcomes for all patients living with this condition. The funding goes to institutions that are part of the Dana-Farber Harvard Cancer Center that includes Massachusetts General Hospital, Brigham and Women's Dana-Farber Cancer Institute and my institution at Bethesda and Deaconess Medical Center and we work across many disciplines with both basic scientists and clinicians to try to advance our understanding of kidney cancer and improve outcomes. The grant is currently in its ninth year of funding. We've been fortunate enough under Dr. Atkins' guidance to have renewed this application at least once. It's a five-year grant. We're now in the process of getting new projects for our next submission and we hope to get it refunded starting in 2014.